774 related articles for article (PubMed ID: 19581407)
1. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies.
Peggs KS; Quezada SA; Chambers CA; Korman AJ; Allison JP
J Exp Med; 2009 Aug; 206(8):1717-25. PubMed ID: 19581407
[TBL] [Abstract][Full Text] [Related]
2. Monotherapeutically nonactive CTLA-4 blockade results in greatly enhanced antitumor effects when combined with tumor-targeted superantigens in a B16 melanoma model.
Sundstedt A; Celander M; Eriksson H; Törngren M; Hedlund G
J Immunother; 2012 May; 35(4):344-53. PubMed ID: 22495392
[TBL] [Abstract][Full Text] [Related]
3. Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4.
Holmgaard RB; Zamarin D; Munn DH; Wolchok JD; Allison JP
J Exp Med; 2013 Jul; 210(7):1389-402. PubMed ID: 23752227
[TBL] [Abstract][Full Text] [Related]
4. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.
Simpson TR; Li F; Montalvo-Ortiz W; Sepulveda MA; Bergerhoff K; Arce F; Roddie C; Henry JY; Yagita H; Wolchok JD; Peggs KS; Ravetch JV; Allison JP; Quezada SA
J Exp Med; 2013 Aug; 210(9):1695-710. PubMed ID: 23897981
[TBL] [Abstract][Full Text] [Related]
5. Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25.
Hannani D; Vétizou M; Enot D; Rusakiewicz S; Chaput N; Klatzmann D; Desbois M; Jacquelot N; Vimond N; Chouaib S; Mateus C; Allison JP; Ribas A; Wolchok JD; Yuan J; Wong P; Postow M; Mackiewicz A; Mackiewicz J; Schadendorff D; Jaeger D; Zörnig I; Hassel J; Korman AJ; Bahjat K; Maio M; Calabro L; Teng MW; Smyth MJ; Eggermont A; Robert C; Kroemer G; Zitvogel L
Cell Res; 2015 Feb; 25(2):208-24. PubMed ID: 25582080
[TBL] [Abstract][Full Text] [Related]
6. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells.
Quezada SA; Peggs KS; Curran MA; Allison JP
J Clin Invest; 2006 Jul; 116(7):1935-45. PubMed ID: 16778987
[TBL] [Abstract][Full Text] [Related]
7. Combined immunotherapy: CTLA-4 blockade potentiates anti-tumor response induced by transcutaneous immunization.
Rausch J; Lopez PA; Bialojan A; Denny M; Langguth P; Probst HC; Schild H; Radsak MP
J Dermatol Sci; 2017 Sep; 87(3):300-306. PubMed ID: 28666747
[TBL] [Abstract][Full Text] [Related]
8. Co-administration of RANKL and CTLA4 Antibodies Enhances Lymphocyte-Mediated Antitumor Immunity in Mice.
Ahern E; Harjunpää H; Barkauskas D; Allen S; Takeda K; Yagita H; Wyld D; Dougall WC; Teng MWL; Smyth MJ
Clin Cancer Res; 2017 Oct; 23(19):5789-5801. PubMed ID: 28634284
[No Abstract] [Full Text] [Related]
9. Enhancement of antitumor immunity by combining anti-cytotoxic T lymphocyte antigen-4 antibodies and cryotreated tumor lysate-pulsed dendritic cells in murine osteosarcoma.
Kawano M; Itonaga I; Iwasaki T; Tsumura H
Oncol Rep; 2013 Mar; 29(3):1001-6. PubMed ID: 23291864
[TBL] [Abstract][Full Text] [Related]
10. Synergistic effects of CTLA-4 blockade with tremelimumab and elimination of regulatory T lymphocytes in vitro and in vivo.
Suarez N; Alfaro C; Dubrot J; Palazon A; Bolaños E; Erro L; Hervas-Stubbs S; Martinez-Forero I; Morales-Kastresana A; Martin-Algarra S; Sangro B; Lecanda F; Perez-Gracia JL; Gonzalez A; Melero I
Int J Cancer; 2011 Jul; 129(2):374-86. PubMed ID: 20853321
[TBL] [Abstract][Full Text] [Related]
11. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells.
Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB
Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085
[TBL] [Abstract][Full Text] [Related]
12. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses.
Sutmuller RP; van Duivenvoorde LM; van Elsas A; Schumacher TN; Wildenberg ME; Allison JP; Toes RE; Offringa R; Melief CJ
J Exp Med; 2001 Sep; 194(6):823-32. PubMed ID: 11560997
[TBL] [Abstract][Full Text] [Related]
13. Combination of CTL-associated antigen-4 blockade and depletion of CD25 regulatory T cells enhance tumour immunity of dendritic cell-based vaccine in a mouse model of colon cancer.
Saha A; Chatterjee SK
Scand J Immunol; 2010 Feb; 71(2):70-82. PubMed ID: 20384858
[TBL] [Abstract][Full Text] [Related]
14. IL36 Cooperates With Anti-CTLA-4 mAbs to Facilitate Antitumor Immune Responses.
Qu Q; Zhai Z; Xu J; Li S; Chen C; Lu B
Front Immunol; 2020; 11():634. PubMed ID: 32351508
[TBL] [Abstract][Full Text] [Related]
15. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
Davila E; Kennedy R; Celis E
Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
[TBL] [Abstract][Full Text] [Related]
16. Ctla-4 blockade plus adoptive T-cell transfer promotes optimal melanoma immunity in mice.
Mahvi DA; Meyers JV; Tatar AJ; Contreras A; Suresh M; Leverson GE; Sen S; Cho CS
J Immunother; 2015; 38(2):54-61. PubMed ID: 25658614
[TBL] [Abstract][Full Text] [Related]
17. Cytotoxic T lymphocyte antigen-4 blockade enhances antitumor immunity by stimulating melanoma-specific T-cell motility.
Pentcheva-Hoang T; Simpson TR; Montalvo-Ortiz W; Allison JP
Cancer Immunol Res; 2014 Oct; 2(10):970-80. PubMed ID: 25038199
[TBL] [Abstract][Full Text] [Related]
18. Murine bone marrow chimeras developing autoimmunity after CTLA-4-blockade show an expansion of T regulatory cells with an activated cytokine profile.
De Somer L; Fevery S; Bullens DM; Rutgeerts O; Lenaerts C; Mathieu C; Boon L; Kasran A; Waer M; Billiau AD
Immunol Lett; 2010 Sep; 133(1):49-53. PubMed ID: 20600326
[TBL] [Abstract][Full Text] [Related]
19. Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages.
Yang YF; Zou JP; Mu J; Wijesuriya R; Ono S; Walunas T; Bluestone J; Fujiwara H; Hamaoka T
Cancer Res; 1997 Sep; 57(18):4036-41. PubMed ID: 9307290
[TBL] [Abstract][Full Text] [Related]
20. Tumor vaccines expressing flt3 ligand synergize with ctla-4 blockade to reject preimplanted tumors.
Curran MA; Allison JP
Cancer Res; 2009 Oct; 69(19):7747-55. PubMed ID: 19738077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
